Book contents
- Frontmatter
- Contents
- Participants
- Declarations of personal interest
- Preface
- 1 Overview and definitions of polycystic ovary syndrome and the polycystic ovary
- 2 Genetics and pathogenesis of polycystic ovary syndrome
- 3 Ethnic variations in the expression of polycystic ovary syndrome
- 4 Quality of life for women with polycystic ovary syndrome
- 5 Insulin resistance, the metabolic syndrome and polycystic ovary syndrome
- 6 Management of polycystic ovary syndrome through puberty and adolescence
- 7 Long-term health risks of polycystic ovary syndrome
- 8 Approaches to lifestyle management in polycystic ovary syndrome
- 9 Management of obesity in polycystic ovary syndrome, including anti-obesity drugs and bariatric surgery
- 10 Definition of hyperandrogenism
- 11 Treatment of hyperandrogenism in polycystic ovary syndrome
- 12 Choices in the treatment of anovulatory polycystic ovary syndrome
- 13 Predictors of ovarian response to ovarian stimulation: progress towards individualised treatment in ovulation induction
- 14 Surgical management of anovulatory infertility in polycystic ovary syndrome
- 15 The role of insulin-sensitising drugs in the treatment of polycystic ovary syndrome
- 16 The role of in vitro maturation of oocytes for anovulatory polycystic ovary syndrome
- 17 Acupuncture and/or herbal therapy as an alternative or complement for relief of polycystic ovary syndrome-related symptoms
- 18 Consensus views arising from the 59th Study Group: Current Management of Polycystic Ovary Syndrome
- Index
14 - Surgical management of anovulatory infertility in polycystic ovary syndrome
Published online by Cambridge University Press: 05 July 2014
- Frontmatter
- Contents
- Participants
- Declarations of personal interest
- Preface
- 1 Overview and definitions of polycystic ovary syndrome and the polycystic ovary
- 2 Genetics and pathogenesis of polycystic ovary syndrome
- 3 Ethnic variations in the expression of polycystic ovary syndrome
- 4 Quality of life for women with polycystic ovary syndrome
- 5 Insulin resistance, the metabolic syndrome and polycystic ovary syndrome
- 6 Management of polycystic ovary syndrome through puberty and adolescence
- 7 Long-term health risks of polycystic ovary syndrome
- 8 Approaches to lifestyle management in polycystic ovary syndrome
- 9 Management of obesity in polycystic ovary syndrome, including anti-obesity drugs and bariatric surgery
- 10 Definition of hyperandrogenism
- 11 Treatment of hyperandrogenism in polycystic ovary syndrome
- 12 Choices in the treatment of anovulatory polycystic ovary syndrome
- 13 Predictors of ovarian response to ovarian stimulation: progress towards individualised treatment in ovulation induction
- 14 Surgical management of anovulatory infertility in polycystic ovary syndrome
- 15 The role of insulin-sensitising drugs in the treatment of polycystic ovary syndrome
- 16 The role of in vitro maturation of oocytes for anovulatory polycystic ovary syndrome
- 17 Acupuncture and/or herbal therapy as an alternative or complement for relief of polycystic ovary syndrome-related symptoms
- 18 Consensus views arising from the 59th Study Group: Current Management of Polycystic Ovary Syndrome
- Index
Summary
Introduction
The management of anovulatory infertility in polycystic ovary syndrome (PCOS) has traditionally involved the use of clomifene citrate and then gonadotrophin therapy or laparoscopic ovarian surgery in those who are clomifene resistant. The principles of therapy are first to optimise health (for example, weight loss for those who are overweight) before commencing therapy and then induce regular unifollicular ovulation, while minimising the risks of ovarian hyperstimulation syndrome and multiple pregnancy. Weight loss improves the endocrine profile and the likelihood of ovulation and a healthy pregnancy.
From the 1930s to the early 1960s, wedge resection of the ovary was the only treatment for PCOS. Wedge resection required a laparotomy and removal of up to 75% of each ovary, and often resulted in extensive pelvic adhesions. The modern-day, minimal access alternative to gonadotrophin therapy for clomifene-resistant PCOS is laparoscopic ovarian surgery, usually employing diathermy or laser. Laparoscopic ovarian surgery has therefore replaced ovarian wedge resection as the surgical treatment for clomifene resistance in women with PCOS. It is free of the risks of multiple pregnancy and ovarian hyperstimulation and does not require intensive ultrasound monitoring. Furthermore, ovarian diathermy is said to be as effective as routine gonadotrophin therapy in the treatment of clomifene-insensitive PCOS, although the evidence for this will be discussed in this chapter.
Keywords
- Type
- Chapter
- Information
- Current Management of Polycystic Ovary Syndrome , pp. 165 - 172Publisher: Cambridge University PressPrint publication year: 2010